How Does Tranexamic Acid Work to Stop Bleeding?

Tranexamic acid stops bleeding by protecting blood clots from being dissolved too quickly. It is a synthetic molecule that mimics the amino acid lysine and works by latching onto the protein plasminogen, preventing plasminogen from binding to fibrin and breaking clots apart. This mechanism makes it different from drugs that help clots form in the first place; tranexamic acid keeps clots intact once they have already been built. The drug is cheap, widely available, and used across an enormous range of bleeding scenarios, from battlefield injuries to heavy periods to elective surgery.

How Tranexamic Acid Protects a Blood Clot

When you bleed, your body assembles a clot out of a protein mesh called fibrin. That clot is meant to be temporary. Your body also runs a cleanup system called fibrinolysis, which uses an enzyme called plasmin to chew through the fibrin mesh and dissolve the clot once the wound has healed. Plasmin does not form spontaneously. It starts as an inactive precursor, plasminogen, which docks onto the fibrin surface through specific attachment points called lysine binding sites. Once plasminogen locks onto fibrin, it gets converted to plasmin and starts breaking the clot down.

Tranexamic acid is shaped enough like lysine that it competes for those same binding sites on plasminogen. When tranexamic acid occupies those sites, plasminogen can no longer attach to fibrin properly, and the conversion to active plasmin slows dramatically.¹ The clot stays put longer, giving the wound more time to heal underneath. The drug does not make blood “stickier” or push the body to create bigger clots. It simply prevents the body’s own cleanup crew from arriving too early and dismantling clots that are still needed.

Why Timing Matters So Much

The single most consistent finding across tranexamic acid research is that the drug works best when given early. The landmark trial establishing this was CRASH-2, which enrolled over 20,000 trauma patients with significant bleeding across 274 hospitals in 40 countries. Overall, all-cause mortality dropped from about 16% in the placebo group to about 14.5% in the tranexamic acid group, and death from bleeding specifically fell as well.²

The effect was strikingly time-dependent. Patients treated within the first hour after injury saw bleeding deaths drop from roughly 7.7% to 5.3%. Those treated between one and three hours still benefited, with bleeding deaths falling from about 6.1% to 4.8%.³ But treatment given after three hours showed no benefit and may even have been harmful. This pattern keeps reappearing in other settings: early tranexamic acid saves lives, and delayed treatment loses most or all of the advantage.

The WOMAN trial found the same dynamic in postpartum hemorrhage. Among more than 20,000 women experiencing serious bleeding after childbirth, tranexamic acid reduced death from bleeding. The benefit was clearest in women who received treatment within three hours, where bleeding deaths fell from about 1.7% to 1.2%.⁴ The biological reason is straightforward: once excessive fibrinolysis has destroyed enough clot material and the patient has lost too much blood, slowing clot breakdown no longer solves the problem. The intervention has to happen while there is still clot to save.

Tranexamic Acid in Surgery

Outside of trauma and obstetrics, surgeons routinely use tranexamic acid to limit blood loss during operations. In hip and femoral surgeries, one trial found that patients given tranexamic acid had dramatically less blood in their surgical drains, averaging about 39 mL compared to roughly 91 mL in the placebo group, and fewer patients needed transfusions.⁵

Heart surgery is another major application. A meta-analysis of trials in patients undergoing off-pump coronary artery bypass found that tranexamic acid cut 24-hour blood loss by more than 200 mL on average compared to placebo and significantly reduced the need for red blood cell and plasma transfusions.⁶ Reducing transfusions matters beyond just the bleeding itself: every transfusion carries a small risk of allergic reaction, infection, or immune complications. A drug that cuts down the number of units a patient needs delivers safety benefits beyond the immediate blood-loss numbers.

Heavy Menstrual Bleeding

One of the most common everyday uses of tranexamic acid is for heavy periods. Women take it as an oral tablet during the heaviest days of their cycle, and it reduces menstrual blood loss by roughly a quarter to more than half, depending on the study. It performs better than anti-inflammatory painkillers and oral progestins taken during the second half of the cycle, though hormonal intrauterine devices still tend to reduce flow more.⁷ The typical regimen is about 4 grams a day for four to five days, beginning on the first day of menstruation.

What makes this use notable is how different it feels from trauma care. In an emergency room, tranexamic acid is given intravenously as quickly as possible to save a life. For heavy periods, it is a tablet you pick up at a pharmacy and take at home. The mechanism is identical in both cases: the drug slows fibrinolysis in the uterine lining, helping the small clots that form when menstrual tissue sheds stay intact longer and reduce flow. It also improves quality of life measures in women who take it, which is worth emphasizing since heavy menstrual bleeding is often undertreated.⁸

What Happens After Traumatic Brain Injury

Traumatic brain injury represents a more complicated story for tranexamic acid. The CRASH-3 trial enrolled over 12,000 patients with head injuries and tested whether tranexamic acid, given within three hours, could reduce deaths. In patients with mild-to-moderate head injuries, it did reduce the risk of death by about 22%. But in patients with severe head injuries, there was no benefit.⁹

A substudy that looked at brain scans tried to figure out whether tranexamic acid was physically preventing brain bleeds from expanding. The results were disappointing on that front: in the overall group, there was no clear evidence that the drug stopped existing bleeds from growing. When the analysis excluded the most severely injured patients (those with unreactive pupils, suggesting devastating brain damage), there was some evidence that tranexamic acid prevented new bleeding events from appearing.¹⁰ The drug did not appear to increase the risk of blood-vessel blockages in the brain, which had been a theoretical worry. The picture in traumatic brain injury is less clear-cut than in trauma or postpartum bleeding, and the benefit seems limited to patients whose injuries are not already catastrophic.

How Your Body Handles the Drug

Tranexamic acid can be given intravenously, injected into muscle, or swallowed as a tablet. Each route gets the drug into your bloodstream at different speeds and efficiencies. When injected into a vein, you get the full dose immediately. Intramuscular injection is nearly as good, with absorption that is fast and essentially complete.¹¹ Oral tablets absorb less completely, with estimates of bioavailability ranging from about 34% to 47% of the dose making it into the blood, depending on the study.¹² This is why oral doses tend to be larger than intravenous ones: you need to swallow more to get the same blood levels.

The drug is mostly eliminated by the kidneys, with over 95% of an intravenous dose showing up in urine. It clears the body relatively quickly, with most elimination happening in the first eight hours. Food does not meaningfully change how well oral tranexamic acid is absorbed, so there is no need to time tablets around meals. For patients with kidney problems, though, the drug lingers longer, and doses may need to be adjusted downward.

Side Effects and Safety Concerns

The most common fear people have about tranexamic acid is that it will cause dangerous blood clots. This is intuitive reasoning: a drug that keeps clots from dissolving might cause clots to form where you do not want them. But the data consistently fails to support this fear. A systematic review and meta-analysis of 216 trials covering more than 125,000 patients found no increase in the risk of blood clots with tranexamic acid. Rates of clotting events were about 2.1% in patients who received tranexamic acid and about 2.0% in control patients, a difference that was not statistically meaningful.¹³ A separate meta-analysis focused on non-surgical patients reached the same conclusion, finding no significant increase in stroke, heart attack, pulmonary embolism, or deep vein thrombosis.¹⁴

A less well-known risk involves seizures. Tranexamic acid, at high enough concentrations, blocks a type of receptor in the brain called the GABA-A receptor. GABA is the brain’s main inhibitory signal, the chemical that tells neurons to calm down. When tranexamic acid interferes with GABA signaling, neurons become more excitable, which can tip over into seizure activity.¹⁵ The drug also appears to bind to glycine receptors, another inhibitory pathway, which may compound the problem.¹⁶ This risk is dose-dependent and most relevant during cardiac surgery, where high doses of tranexamic acid are sometimes used and the drug can reach the brain in significant concentrations. At the standard doses used in trauma or obstetrics, seizures are rare.

How It Compares to Other Antifibrinolytic Drugs

Tranexamic acid is not the only drug that blocks fibrinolysis. Aminocaproic acid works through a similar mechanism, also competing for lysine binding sites on plasminogen. In practice, though, the two drugs are not interchangeable. A meta-analysis of nine randomized trials in adult heart-surgery patients found that tranexamic acid reduced 24-hour blood loss and total red blood cell transfusions significantly more than aminocaproic acid, with no difference in neurological, kidney, heart, or clotting complications between the two.¹⁷

In children undergoing heart surgery, the picture is less clear. One trial found no statistically significant differences in blood loss, re-operation rates, or complications between the two drugs, though there was a numerically higher (but not statistically significant) seizure rate with tranexamic acid.¹⁸ Aprotinin, a third antifibrinolytic that was once widely used, was pulled from many markets after trials linked it to increased kidney damage and death, leaving tranexamic acid and aminocaproic acid as the main remaining options. Tranexamic acid has ended up the dominant choice worldwide, partly on effectiveness and partly because it has the strongest trial evidence base behind it.

Prehospital Use and Getting the Drug to Patients Faster

Because timing is so critical, a growing push in emergency medicine is to give tranexamic acid before the patient reaches the hospital. Paramedics and military medics have started carrying it, and reviews of the evidence suggest that prehospital administration in adult trauma reduces early all-cause mortality without increasing clotting risks.¹⁹ Research in pediatric trauma is less mature, but a recent systematic review found potential mortality benefits in children as well, while flagging the need for better data on optimal dosing and timing for younger patients.²⁰

Novel delivery methods are also being explored. One team has developed a portable electrospinning device that sprays nanofiber mats loaded with tranexamic acid and zinc directly onto wounds. The idea is to deliver the drug right at the wound surface while also providing a physical wound dressing, combining clot protection with antibacterial zinc release.²¹ This is experimental, but it illustrates the direction the field is heading: getting tranexamic acid to the bleeding site as fast and directly as possible.

Cost-Effectiveness in Low-Resource Settings

Tranexamic acid is a generic drug. A dose costs a few dollars at most, and often far less. That cheapness has made it particularly interesting for global health, where expensive interventions are simply not an option. Economic analyses of the WOMAN trial’s postpartum hemorrhage data estimated that routinely giving tranexamic acid to women with postpartum bleeding in Nigeria and Pakistan was highly cost-effective, with the incremental cost per quality-adjusted life year gained well below the threshold for cost-effectiveness in both countries.²²

In sub-Saharan Africa, the calculus is even more compelling. In countries with chronic blood shortages, tranexamic acid does not just reduce the need for transfusions; it reduces deaths that would have occurred because blood simply was not available. Even in settings where blood supply is adequate, using tranexamic acid saves money by avoiding the considerable cost of collecting, testing, and administering blood products, and it averts the blood-borne infections that come with transfusions in regions where screening is less reliable.²³

Uses Beyond Bleeding

Tranexamic acid has found a second life in dermatology, where its ability to interfere with melanin production has made it a treatment for melasma and other hyperpigmentation conditions. The connection is not as strange as it sounds. Plasminogen plays roles outside of clot dissolution, including in pathways that stimulate melanocytes to produce pigment. By blocking plasminogen activity, tranexamic acid can dial down melanin synthesis. Laboratory research has shown that the drug also inhibits signaling through VEGF receptors on melanocytes, reducing both blood vessel growth and melanin production.²⁴

Dermatologists use tranexamic acid orally, topically, or as microinjections into the skin. Its anti-inflammatory and anti-angiogenic properties have also led to it being tried for rosacea, post-inflammatory hyperpigmentation from acne, and hereditary angioedema.²⁵ The oral doses used for skin conditions are generally lower than those used for bleeding, and long-term safety data in this context is still being gathered. It is a reminder that a drug’s mechanism can ripple through the body in ways that the original designers never anticipated, turning a bleeding treatment into a skincare ingredient.